Skip to content
RecruitingNot applicable

At-Home tDCS as Maintenance Therapy

NCT07269964 · MaintenanceDC · Technical University of Munich

Recruiting
Status
Accepting participants
Not applicable
Phase
30
Target enrolment
2
Study sites
Outside the US

What it is testing

Summary

The primary purpuse of this pilot study is to find out whether a home-based transcranial direct current stimulation (tDCS) program is feasible and well tolerated as maintenance therapy and whether there are early signs that it helps maintain the clinical clinical benefits achieved during successful acute inpatient treatment. Participant population: Adults (18+) with depressive disorder who had already improved/stabilized after acute treatment at our clinic (esketamine, repetitive transcranial magnetic stimulation , or electroconvulsive therapy). Main questions: Feasibility: Do participants reliably complete the home program and stay in the study? Preliminary effectiveness: Do improvements of depressive symptoms hold up over the 4-week treatment and 2-week follow-up (based on self-report and clinician-rated scales)? Participants receive standardized instruction from trained staff and a portable tDCS device (with cap and small sponge electrodes) and complete 20 home sessions over 4 weeks (5 per week), each 30 minutes at a very low current (2 mA); the device gently ramps current up/down for comfort. During treatment, participants use a smartphone app with step-by-step guidance and reminders; sessions are automatically logged. They will also fill out short weekly self-rating questionnaires and join brief phone check-ins every 2 weeks. Where: Department and Outpatient Clinic of Psychiatry and Psychotherapy, Klinikum rechts der Isar, Technical University of Munich Safety \& data privacy: The device monitors electrode contact and pauses automatically if contact is poor. Typical sensations can include mild tingling or redness. The app stores anonymized session data so the care team can track progress; no personal data are exchanged between the app and the stimulator, and access is via a secure clinical portal.

Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.

What counts as success

Primary outcome measures

  • Feasibility, number of completed sessions

    Measured over 4 weeks from baseline

A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.

Who can take part

Eligibility, as published

18 Years
Ages
All
Sex
Not accepted
Healthy volunteers
Inclusion Criteria: * Adults (≥18 years). * Diagnosis according to ICD-10: recurrent depressive disorder, severe depressive disorder, schizoaffective disorder (depressive episode) or bipolar affective disorder (depressive episode). * Clear indication for maintenance therapy after successful acute treatment (esketamine, rTMS, or ECT) with remission/improvement of symptoms. * Capacity to provide informed consent, confirmed in a physician-led consent discussion. Exclusion Criteria: * Currently in the acute treatment phase of an affective disorder and non-response to previous treatments. * Currently clinically relevant Axis II disorders. * Suicidal risk, including suicidal ideation. * Contraindications for tDCS: e.g., skin disease at electrode sites, cochlear implants. * Neurological, somatic, or psychiatric comorbidities that could compromise validity or safety.

Where

2 study sites

FacilityCityRegionCountry
Technical University of Munich, TUM School of Medicine and Health, Department of Psychiatry and Psychotherapy, Munich,MünchenBavariaGermany
Department of Psychiatry and Psychotherapy, Technical University of Munich, University HospitalMünchenGermany

On the registry

Contact the trial directly

This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.

Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.

NCT07269964 on ClinicalTrials.gov →

Last updated in the registry 2025-12-08. Registry records change; this page reflects the data build of 2026-08-25.

Related

Where this trial sits